



10. (original) The method according to Claim 9, wherein said leukemia patient is a chronic myelogenous leukemia patient.

11-14. (canceled)

15. (original) A method of phenotyping a leukemic condition, the method comprising:  
combining a hematologic sample from a patient suspected of said leukemic condition with specific binding members that are sufficient to distinguish the distribution of cells with hematopoietic stem and progenitor subsets;  
determining the distribution of progenitor cells between said subsets,  
wherein the distribution of progenitor cells is indicative of the phenotype of said leukemic condition.

16. (original) The method according to Claim 15, wherein said leukemic condition is MDS.

17. (original) The method according to Claim 15, wherein said leukemic condition is a myeloid leukemia.

18. (original) The method according to Claim 15, wherein said myeloid leukemia is CML or CMML.

19. (original) The method according to Claim 15, wherein said hematopoietic stem and progenitor subsets include one or more of HSC, CMP, MEP and GMP.

20. (original) The method according to Claim 15, wherein said specific binding members are antibodies.

21. (original) The method according to Claim 20, wherein said antibodies include specificities for CD34 and CD38.

22. (original) The method according to Claim 21, wherein said antibodies further include specificities for IL-3R and CD45RA.

23. (original) The method according to Claim 21, further comprising antibodies specific for a lineage panel.

24-25. (canceled)

26. (original) A method of inhibiting the proliferation of an LSC, the method comprising:  
contacting said LSC with an agent that inhibit the Wnt/ $\beta$ -catenin pathway.

27. (original) The method according to Claim 26, wherein said agent comprises axin, a polynucleotide encoding axin and operably linked to a transcriptional regulatory element expressed in said LSC, or a mimetic of axin.

28. (new) A method of phenotyping a leukemic condition, the method comprising:  
introducing into a hematologic sample from a patient suspected of said leukemic condition  
detecting the presence of expression of said detectable marker,  
wherein expression of said marker is indicative of the phenotype of said leukemic condition.

29. (new) The method according to Claim 28, wherein said marker is a fluorescence producing protein.

30. (new) The method according to Claim 28, wherein said transcriptional response element regulated by  $\beta$ -catenin is a LEF-1/TCF binding sequence.

31. (new) The method according to Claim 28, wherein said leukemic condition is MDS.

32. (new) The method according to Claim 28, wherein said leukemic condition is a myeloid leukemia.

33. (new) The method according to Claim 28, wherein said myeloid leukemia is CML or CMML.

34. (new) The method according to Claim 28, wherein said detecting is performed by flow cytometry.

35. (new) The method according to Claim 28, wherein said detecting is performed by confocal microscopy.